William H. Rastetter

Companies

• Dare Bioscience, Inc.Board member Apr 10, 2014 to now¹
• Fate TherapeuticsBoard member Sep 30, 2013 to now²
• Regulus Therapeutics Inc.Board member Apr 1, 2013 to now³
• Neurocrine BiosciencesBoard member Feb 8, 2010 to now⁴
• IlluminaBoard member Jun 9, 2006 to Jan 4, 2016⁵

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

• Neurocrine Biosciences NBIX43,678 shares⁶$6.0M at $137.36May 21, 2026
• FTFate Therapeutics FATE495,603 shares⁷$931.7K at $1.88May 6, 2026
• DBDare Bioscience, Inc. DARE39,721 shares⁸$27.4K at $0.69Jun 30, 2026
• RTRegulus Therapeutics Inc.0 shares⁹Jun 25, 2025

As of each latest filing. The line shows shares held over time.

Recent filings

• Jun 30, 2026Granted 38,862 shares of Dare Bioscience, Inc.⁸
• May 21, 2026Exercised options 3,318 shares of Neurocrine Biosciences⁶
• May 5, 2026Exercised options 25,000 shares at $1.69 of Fate Therapeutics⁷
• Nov 5, 2025Sold 18,000 shares at $151.82 of Neurocrine Biosciences¹⁰
• Nov 5, 2025Exercised options 18,000 shares at $47.89 of Neurocrine Biosciences¹⁰
• Jun 25, 2025Returned to company 57,292 shares of Regulus Therapeutics Inc.⁹
• Jun 25, 2025U 44,264 shares of Regulus Therapeutics Inc.⁹
• May 22, 2025Exercised options 2,869 shares of Neurocrine Biosciences¹¹
• May 5, 2025Sold 30,000 shares at $110.20 of Neurocrine Biosciences¹²
• May 5, 2025Exercised options 30,000 shares at $42.76 of Neurocrine Biosciences¹²
• Apr 30, 2025Granted 62,500 shares of Regulus Therapeutics Inc.¹³
• Aug 15, 2024Sold 14,250 shares at $146.69 of Neurocrine Biosciences¹⁴
• Jan 2, 2024Sold 11,044 shares at $131.47 of Neurocrine Biosciences¹⁵
• Jan 2, 2024Exercised options 20,000 shares at $12.98 of Neurocrine Biosciences¹⁵
• May 1, 2023Sold 4,300 shares at $101.43 of Neurocrine Biosciences¹⁶
• May 1, 2023Exercised options 7,625 shares at $12.71 of Neurocrine Biosciences¹⁶
• Apr 21, 2023Sold 6,034 shares at $105.04 of Neurocrine Biosciences¹⁷
• Apr 21, 2023Exercised options 10,765 shares at $12.71 of Neurocrine Biosciences¹⁷
• Apr 19, 2023Sold 903 shares at $105.00 of Neurocrine Biosciences¹⁷
• Apr 19, 2023Exercised options 1,610 shares at $12.71 of Neurocrine Biosciences¹⁷
• Jun 9, 2022Granted 8,650 shares of Fate Therapeutics¹⁸
• Apr 1, 2022Sold 10,728 shares at $94.93 of Neurocrine Biosciences¹⁹
• Apr 1, 2022Exercised options 20,000 shares at $6.66 of Neurocrine Biosciences¹⁹